Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Fierce Biotech

March 7, 2023

Fierce Biotech Fundraising Tracker ’23

Pharmaceutical Technology

February 23, 2023

New pipeline agents expected to differentiate the UC market

GlobalCapital

February 23, 2023

Abivax raises EUR 130M in ABB amidst flurry of pharma deals (subscribers only)

European Biotechnology:

February 23, 2023

Abivax SA raises €130m to advance obefazimod to Phase III

ThePharmaLetter

February 23, 2023

Another oversubscribed financing for Abivax

  • 1
  • 2
  • 3
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn